Real-world safety, dose reduction determinants, and effectiveness of first-line osimertinib in EGFR -mutated non-small-cell lung cancer: a single-center retrospective cohort study
JAAD International
· Elsevier
Аннотация
Publication date: September 2026 Source: International Journal of Lung Cancer, Volume 1, Issue 3 Author(s): Yuya Murase, Kazuhiko Shibata, Keiichi Iwasa, Yasutaka Shiba, Junya Suzuki, Satoshi Tanaka, Akihito Bando, Yukari Nakagawa, Naoya Tachimura, Seiji Yano
Читать у издателя →
Цитировать
Получайте новые статьи по теме «Дерматология»
Подписка, поиск по ключевым словам и избранное — в Telegram-боте Articlium.
Открыть в Telegram
Цитирование
✕
ГОСТ
APA
MLA
BibTeX
Real-world safety, dose reduction determinants, and effectiveness of first-line osimertinib in EGFR -mutated non-small-cell lung cancer: a single-center retrospective cohort study. // JAAD International. – URL: https://www.sciencedirect.com/science/article/pii/S3117504X26000392?dgcid=rss_sd_all
Real-world safety, dose reduction determinants, and effectiveness of first-line osimertinib in EGFR -mutated non-small-cell lung cancer: a single-center retrospective cohort study. JAAD International. https://www.sciencedirect.com/science/article/pii/S3117504X26000392?dgcid=rss_sd_all
“Real-world safety, dose reduction determinants, and effectiveness of first-line osimertinib in EGFR -mutated non-small-cell lung cancer: a single-center retrospective cohort study.” JAAD International.
@article{article5827,
title = {Real-world safety, dose reduction determinants, and effectiveness of first-line osimertinib in EGFR -mutated non-small-cell lung cancer: a single-center retrospective cohort study},
journal = {JAAD International},
url = {https://www.sciencedirect.com/science/article/pii/S3117504X26000392?dgcid=rss_sd_all}
}